PubRank

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Clinical Trial ID NCT00134056

PubWeight™ 29.31‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00134056

Top papers

Rank Title Journal Year PubWeight™‹?›
1 G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011 3.31
2 Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 2013 2.29
3 Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 2014 2.19
4 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
5 Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2010 1.86
6 Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 2009 1.69
7 Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2013 1.40
8 Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 2011 1.34
9 Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 2011 1.31
10 Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 1.04
11 The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. BJU Int 2012 1.00
12 Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010 1.00
13 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
14 Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010 0.96
15 Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012 0.95
16 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
17 Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol 2013 0.87
18 Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011 0.87
19 Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist 2011 0.85
20 Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst 2014 0.83
21 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
22 Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol 2010 0.79
23 Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside? Int J Mol Sci 2016 0.75
Next 100